Selenium–Platinum Coordination Compounds as Novel Anticancer Drugs: Selectively Killing Cancer Cells via a Reactive Oxygen Species (ROS)‐Mediated Apoptosis Route. Issue 8 (20th May 2014)

• Record Type: Journal Article
• Authors: Zeng, Lingwu; Li, Yang; Li, Tianyu; Cao, Wei; Yi, Yu; Geng, Weijia; Sun, Zhiwei; Xu, Huaping
• Is Part Of: Chemistry, an Asian journal. Volume 9:Issue 8(2014:Aug.)
• Page Start: 2295
• Page End: 2302
• Publication Date: 2014-05-20
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1002/asia.201402256
• Languages: English
• ISSNs: 1861-4728

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>We report the preparation of selenium‐containing platinum‐based anticancer drug EG‐Se/Pt. EG‐Se/Pt was obtained from the coordination of selenium‐containing molecules (EG‐Se) with cisplatin (CDDP). The structure of EG‐Se/Pt was characterized by ¹H and ⁷⁷Se NMR spectroscopy, XPS, ESI‐MS, and MALDI‐TOF. In aqueous solution, EG‐Se/Pt self‐assembles to form spherical aggregates. EG‐Se/Pt shows enhanced stability against dilution and high salt concentration compared with EG‐Se. EG‐Se/Pt induces cell apoptosis via reactive oxygen species (ROS), which leads to high selectivity between cancer cells and normal cells in cytotoxicity assays. More importantly, EG‐Se/Pt effectively inhibits tumor growth in vivo in tumor‐bearing mice. It is anticipated that tuning the ROS level through the assembly of selenium‐containing molecules can be a general method to realize anticancer selectivity.</p> </abstract>